- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.06. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | Elutia Inc.: Elutia to Present at Planet MicroCap Showcase 2026 on June 17th | 2 | GlobeNewswire (USA) | ||
| 18.05. | Elutia Inc.: Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| ELUTIA Aktie jetzt für 0€ handeln | |||||
| 15.05. | Elutia Reports Q1 2026 Results: Full Earnings Call Transcript | 3 | Benzinga.com | ||
| 14.05. | Elutia reports Q1 results, expects FDA clearance for NXT-41 | 1 | Investing.com | ||
| 14.05. | Elutia: EPS verfehlt Schätzungen um 0,02 $ - Umsatz besser als erwartet | 1 | Investing.com Deutsch | ||
| 14.05. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Elutia Inc.: Elutia to Present at the 16th Annual LD Micro Invitational on May 18th | 1 | GlobeNewswire (USA) | ||
| 14.05. | LD Micro: Elutia to Present at the 16th Annual LD Micro Invitational May 18th | 323 | Newsfile | Gaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Elutia Inc. (NASDAQ: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy... ► Artikel lesen | |
| 25.03. | ELUTIA INC. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 13.03. | ELUTIA INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 13.03. | Elutia Inc.: Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 12.03. | Elutia outlines launch timeline for NXT-41x in $1.5B breast reconstruction market while strengthening leadership team | 1 | Seeking Alpha | ||
| 11.03. | Elutia Q4 2025 slides: $88M sale funds pivot to breast reconstruction | 1 | Investing.com | ||
| 11.03. | Earnings Call Transkript: Elutia übertrifft Prognosen für Q4 2025 deutlich - Aktie reagiert verhalten | 4 | Investing.com Deutsch | ||
| 11.03. | Elutia GAAP EPS of $1.48 beats by $1.62, revenue of $3.3M in-line | 2 | Seeking Alpha | ||
| 10.03. | Exploring Elutia's Earnings Expectations | 1 | Benzinga.com | ||
| 04.03. | Elutia regains full Nasdaq listing compliance | 1 | Seeking Alpha | ||
| 04.03. | Elutia erfüllt wieder die Nasdaq-Notierungsanforderungen | 1 | Investing.com Deutsch | ||
| 04.03. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 75,24 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| QIAGEN | 36,405 | -0,72 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| ERASCA | 18,530 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| VERA THERAPEUTICS | 42,000 | 0,00 % | Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner | BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,250 | 0,00 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| TARSUS PHARMACEUTICALS | 58,13 | -0,02 % | Tarsus Acquires iRenix Medical To Expand Eye Care Pipeline With Late-Stage IRX-101 | ||
| ARCUTIS BIOTHERAPEUTICS | 27,740 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months | FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,64 | -0,01 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| MBX BIOSCIENCES | 61,05 | 0,00 % | MBX Biosciences Aktie erreicht Rekordhoch bei 59,55 USD | ||
| COGENT BIOSCIENCES | 38,880 | +0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| VOR BIOPHARMA | 19,140 | 0,00 % | Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors | BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 63,44 | 0,00 % | Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 20,360 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering | ZUG, Switzerland, June 23, 2026 - MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and... ► Artikel lesen | |
| BEAM THERAPEUTICS | 32,670 | -0,03 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| ENLIVEN THERAPEUTICS | 51,09 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen |
Das Unternehmen ELUTIA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,69 % bei einem Aktienkurs von 0,989 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELUTIA INC finden Sie auf Wallstreet Online.